Telatinib sustained-release implantation agent for treating solid tumors

Telatinib sustained-release implantation agent for treating solid tumors

The invention relates to a teratinib sustained release implant for treating solid tumors, which is characterized in that the sustained release implant contains teratinib and sustained-release excipient of effective anticancer amount and certain amount of sustained release regulator. The solid tumors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HOU HONGCHUN, KONG QINGZHONG
Format: Patent
Sprache:chi ; eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator HOU HONGCHUN
KONG QINGZHONG
description The invention relates to a teratinib sustained release implant for treating solid tumors, which is characterized in that the sustained release implant contains teratinib and sustained-release excipient of effective anticancer amount and certain amount of sustained release regulator. The solid tumors comprise lung cancer, esophageal cancer, carcinoma ventriculi, liver cancer, mammary cancer, oophoroma, prostatic carcinoma, carcinoma of urinary bladder and colorectal cancer. The sustained-release excipient is mainly one of or the combination of copolymer of glycollic acid and glycolic acid, Polifeprosan, poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co-propyl phosphate), and the teratinib is slowly released into local tumor during the degradation and absorption process, therefore the invention not only obviously reduces toxic reaction of the whole body, but also maintains effective drug concentration at the local tumor. The sustained release implant is arranged in the local tumor, which not only reduces
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN101219106A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN101219106A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN101219106A3</originalsourceid><addsrcrecordid>eNqNizEKwkAQRbexEPUO4wECWQXBMgQllVX6MJqfsLCZXXYm91fBA1i94r23dV2PyBYkPElXNQ6CsSqIYAWFJUcW-_gkxDPEaEqFrOC7zKQphpFsXVLRvdtMHBWHH3fueL_1bVchpwGa-QWBDe3D1_7kr76-NOd_mjcFFjT8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Telatinib sustained-release implantation agent for treating solid tumors</title><source>esp@cenet</source><creator>HOU HONGCHUN ; KONG QINGZHONG</creator><creatorcontrib>HOU HONGCHUN ; KONG QINGZHONG</creatorcontrib><description>The invention relates to a teratinib sustained release implant for treating solid tumors, which is characterized in that the sustained release implant contains teratinib and sustained-release excipient of effective anticancer amount and certain amount of sustained release regulator. The solid tumors comprise lung cancer, esophageal cancer, carcinoma ventriculi, liver cancer, mammary cancer, oophoroma, prostatic carcinoma, carcinoma of urinary bladder and colorectal cancer. The sustained-release excipient is mainly one of or the combination of copolymer of glycollic acid and glycolic acid, Polifeprosan, poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co-propyl phosphate), and the teratinib is slowly released into local tumor during the degradation and absorption process, therefore the invention not only obviously reduces toxic reaction of the whole body, but also maintains effective drug concentration at the local tumor. The sustained release implant is arranged in the local tumor, which not only reduces</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2008</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20080716&amp;DB=EPODOC&amp;CC=CN&amp;NR=101219106A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20080716&amp;DB=EPODOC&amp;CC=CN&amp;NR=101219106A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HOU HONGCHUN</creatorcontrib><creatorcontrib>KONG QINGZHONG</creatorcontrib><title>Telatinib sustained-release implantation agent for treating solid tumors</title><description>The invention relates to a teratinib sustained release implant for treating solid tumors, which is characterized in that the sustained release implant contains teratinib and sustained-release excipient of effective anticancer amount and certain amount of sustained release regulator. The solid tumors comprise lung cancer, esophageal cancer, carcinoma ventriculi, liver cancer, mammary cancer, oophoroma, prostatic carcinoma, carcinoma of urinary bladder and colorectal cancer. The sustained-release excipient is mainly one of or the combination of copolymer of glycollic acid and glycolic acid, Polifeprosan, poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co-propyl phosphate), and the teratinib is slowly released into local tumor during the degradation and absorption process, therefore the invention not only obviously reduces toxic reaction of the whole body, but also maintains effective drug concentration at the local tumor. The sustained release implant is arranged in the local tumor, which not only reduces</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2008</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNizEKwkAQRbexEPUO4wECWQXBMgQllVX6MJqfsLCZXXYm91fBA1i94r23dV2PyBYkPElXNQ6CsSqIYAWFJUcW-_gkxDPEaEqFrOC7zKQphpFsXVLRvdtMHBWHH3fueL_1bVchpwGa-QWBDe3D1_7kr76-NOd_mjcFFjT8</recordid><startdate>20080716</startdate><enddate>20080716</enddate><creator>HOU HONGCHUN</creator><creator>KONG QINGZHONG</creator><scope>EVB</scope></search><sort><creationdate>20080716</creationdate><title>Telatinib sustained-release implantation agent for treating solid tumors</title><author>HOU HONGCHUN ; KONG QINGZHONG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN101219106A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2008</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HOU HONGCHUN</creatorcontrib><creatorcontrib>KONG QINGZHONG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HOU HONGCHUN</au><au>KONG QINGZHONG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Telatinib sustained-release implantation agent for treating solid tumors</title><date>2008-07-16</date><risdate>2008</risdate><abstract>The invention relates to a teratinib sustained release implant for treating solid tumors, which is characterized in that the sustained release implant contains teratinib and sustained-release excipient of effective anticancer amount and certain amount of sustained release regulator. The solid tumors comprise lung cancer, esophageal cancer, carcinoma ventriculi, liver cancer, mammary cancer, oophoroma, prostatic carcinoma, carcinoma of urinary bladder and colorectal cancer. The sustained-release excipient is mainly one of or the combination of copolymer of glycollic acid and glycolic acid, Polifeprosan, poly (L-lactide-co-ethyl phosphate), poly (L-lactide-co-propyl phosphate), and the teratinib is slowly released into local tumor during the degradation and absorption process, therefore the invention not only obviously reduces toxic reaction of the whole body, but also maintains effective drug concentration at the local tumor. The sustained release implant is arranged in the local tumor, which not only reduces</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN101219106A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Telatinib sustained-release implantation agent for treating solid tumors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T11%3A51%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HOU%20HONGCHUN&rft.date=2008-07-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN101219106A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true